PE20040402A1 - Procedimientos para reducir la incidencia de cerdos mortinatos mediante el uso de antagonistas del receptor de la progesterona - Google Patents
Procedimientos para reducir la incidencia de cerdos mortinatos mediante el uso de antagonistas del receptor de la progesteronaInfo
- Publication number
- PE20040402A1 PE20040402A1 PE2003000962A PE2003000962A PE20040402A1 PE 20040402 A1 PE20040402 A1 PE 20040402A1 PE 2003000962 A PE2003000962 A PE 2003000962A PE 2003000962 A PE2003000962 A PE 2003000962A PE 20040402 A1 PE20040402 A1 PE 20040402A1
- Authority
- PE
- Peru
- Prior art keywords
- hours
- progesterone receptor
- deadly
- pigs
- incidence
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 229940123788 Progesterone receptor antagonist Drugs 0.000 title abstract 2
- 241000282887 Suidae Species 0.000 title 1
- 230000002498 deadly effect Effects 0.000 title 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 abstract 1
- RCOWGILQXUPXEW-FUSOFXSQSA-N (8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-[(z)-3-hydroxyprop-1-enyl]-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]2(O)\C=C/CO)[C@]2(C)C1 RCOWGILQXUPXEW-FUSOFXSQSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229950001701 lilopristone Drugs 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- 229950011093 onapristone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Feed For Specific Animals (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Fodder In General (AREA)
Abstract
SE REFIERE A UN PROCEDIMIENTO PARA INDUCIR EL PARTO EN CERDAS PRENADAS, QUE DARA COMO RESULTADO EL NACIMIENTO DE LA PRIMERA CRIA EN UN NUMERO PREDECIBLE DE HORAS, APROXIMADAMENTE ENTRE 12 HORAS Y 22 HORAS. DICHO PROCESO COMPRENDE: 1)LA ADMINISTRACION DE UN ANTAGONISTA DEL RECEPTOR DE PROGESTERONA A LAS CERDAS PRENADAS QUE TIENEN AL MENOS 112 DIAS DESPUES DEL APAREAMIENTO, SIENDO DICHO ANTAGONISTA, SELECCIONADO DE: RU38486, ZK230211, ZK98299, ZK98774, ZK137316, ZK112993, J867, J956, LGOO1447, LG120753, ORG33628, MIFEPRISTONA, ONAPRISTONA, LILOPRISTONA Y COMBINACIONES DE LOS MISMOS, EL CUAL PUEDE SER ADMINISTRADO UNA O DOS VECES, SIENDO LA DOSIS UNICA APROXIMADA ENTRE 0,001 mg/kg Y 15 mg/kg DE PESO CORPORAL Y APLICADA 20 A 25 HORAS ANTES DEL NACIMIENTO Y CUANDO SE HACE EN DOS ADMINISTRACIONES, LA PRIMERA ES 30 A 40 HORAS ANTES DEL NACIMIENTO Y LA SEGUNDA APROXIMADAMENTE 9 A 15 HORAS ANTES DEL NACIMIENTO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41324902P | 2002-09-24 | 2002-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040402A1 true PE20040402A1 (es) | 2004-06-26 |
Family
ID=32043223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000962A PE20040402A1 (es) | 2002-09-24 | 2003-09-19 | Procedimientos para reducir la incidencia de cerdos mortinatos mediante el uso de antagonistas del receptor de la progesterona |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040074447A1 (es) |
| AR (1) | AR041344A1 (es) |
| AU (1) | AU2003263430A1 (es) |
| GT (1) | GT200300213A (es) |
| PA (1) | PA8581501A1 (es) |
| PE (1) | PE20040402A1 (es) |
| TW (1) | TW200412977A (es) |
| UY (1) | UY27996A1 (es) |
| WO (1) | WO2004028543A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3337450A1 (de) * | 1983-10-12 | 1985-04-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Prostaglandine und antigestagene fuer den schwangerschaftsabbruch |
| US4870068A (en) * | 1986-05-22 | 1989-09-26 | Sterling Drug Inc. | Method of regulating fertility in swine using epostane |
| US4870066A (en) * | 1986-08-11 | 1989-09-26 | The University Of Kentucky Research Foundation | Method and composition for safely delaying parturition and synchronizing farrowing in swine |
| US5795881A (en) * | 1987-06-16 | 1998-08-18 | Schering Aktiengesellschaft | Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epostane type |
| FR2659233B1 (fr) * | 1990-03-06 | 1994-01-21 | Roussel Uclaf | Nouvelle utilisation de composes anti-progestomimetiques chez les animaux d'elevage. |
| US5369128A (en) * | 1993-06-21 | 1994-11-29 | Iowa State University Research Foundation, Inc. | Method of synchronizing farrowing in swine |
-
2003
- 2003-09-02 PA PA20038581501A patent/PA8581501A1/es unknown
- 2003-09-12 WO PCT/IB2003/004004 patent/WO2004028543A1/en not_active Ceased
- 2003-09-12 AU AU2003263430A patent/AU2003263430A1/en not_active Abandoned
- 2003-09-18 TW TW092125781A patent/TW200412977A/zh unknown
- 2003-09-19 PE PE2003000962A patent/PE20040402A1/es not_active Application Discontinuation
- 2003-09-22 UY UY27996A patent/UY27996A1/es not_active Application Discontinuation
- 2003-09-22 AR ARP030103438A patent/AR041344A1/es not_active Application Discontinuation
- 2003-09-23 US US10/668,622 patent/US20040074447A1/en not_active Abandoned
- 2003-09-24 GT GT200300213A patent/GT200300213A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003263430A1 (en) | 2004-04-19 |
| TW200412977A (en) | 2004-08-01 |
| AR041344A1 (es) | 2005-05-11 |
| US20040074447A1 (en) | 2004-04-22 |
| GT200300213A (es) | 2004-05-18 |
| WO2004028543A1 (en) | 2004-04-08 |
| PA8581501A1 (es) | 2004-04-23 |
| UY27996A1 (es) | 2004-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE284698T1 (de) | Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten | |
| CO2021008988A2 (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| NO20052019L (no) | Blanding for a inhibere sekresjon av magesyre | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| NO20070578L (no) | Oral doseringsform sikret mot misbruk inneholdende (1,2R)-3-(3-dimetylammino-l-etyl-2-metyl-propyl)-fenol | |
| CO2021006482A2 (es) | Ureas cíclicas | |
| AR057060A1 (es) | Composiciones de tanaproget que contienen etinil estradiol | |
| BR9509019B1 (pt) | comprimido isento de solventes orgÂnicos. | |
| AR077611A1 (es) | Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso. | |
| Vedantham et al. | Posttraumatic stress disorder, trauma exposure, and the current health of Canadian bus drivers | |
| Uygur et al. | Leflunomide—an immunomodulator—induces regression of endometrial explants in a rat model of endometriosis | |
| RU2019121690A (ru) | Дексмедетомидин или медетомидин для применения для лечения сепарационной тревожности у собак | |
| JP2021020945A5 (ja) | エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物 | |
| NO20070688L (no) | Nye tetrahydrokarbazolderivater med forbedret biologisk aktivitet og forbedret loselighet som ligander for G-proteinkoblede reseptorer (GPCRS) | |
| MA53010B1 (fr) | Formulations d'un inhibiteur de axl/mer | |
| Gómez-Fernández et al. | Efecto de la immunocastración y de la castración quirúrgica sobre los rendimientos productivos y la calidad de la canal en cerdas Ibéricas de cebo | |
| RU2020120156A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена | |
| Ottani et al. | Modulatory activity of sildenafil on copulatory behaviour of both intact and castrated male rats | |
| Oberlander et al. | Prenatal and breast milk morphine exposure following maternal intrathecal morphine treatment | |
| PE20040402A1 (es) | Procedimientos para reducir la incidencia de cerdos mortinatos mediante el uso de antagonistas del receptor de la progesterona | |
| AR043395A1 (es) | Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii | |
| JP2005529067A5 (es) | ||
| AR044450A1 (es) | Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas | |
| AR109688A1 (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
| HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |